Physician profile
Dawn Suisun Queen
NPI 1396372827
$3,277.29
in general payments reported to CMS, 2019-2025
25 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $822 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.78 | 2024-2025 | |
| Janssen Biotech, INC. | $429.16 | 2025 | Tremfya |
| Lilly USA, LLC | $224.58 | 2024-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $195.76 | 2024 | Vtama |
| Pfizer INC. | $170.08 | 2024-2025 | |
| Organon LLC | $157.53 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $145.23 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $137.79 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $125.11 | 2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $122.58 | 2025 | |
| Ucb, INC. | $109.84 | 2024-2025 | Bimzelx |
| Botanix Sb INC | $98.52 | 2025 | Sofdra |
| Incyte Corporation | $97.12 | 2025 | Opzelura |
| Leo Pharma INC. | $91.25 | 2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.43 | 2025 | Cabtreo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $64.61 | 2024-2025 | Klisyri |
| Genzyme Corporation | $53.22 | 2024 | |
| Sun Pharmaceutical Industries INC. | $52.18 | 2025 | |
| Journey Medical Corporation | $43.40 | 2025 | |
| Fidia Pharma USA INC. | $40.82 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $26.97 | 2025 | Libtayo |
| Arcutis Biotherapeutics, INC. | $25.47 | 2025 | Zoryve |
| Amgen INC. | $24.00 | 2024 | Otezla |
| Cipher Pharmaceuticals US LLC | $14.16 | 2025 | Spinosad, Natroba |
| Mayne Pharma Commercial LLC | $12.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Queen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.